Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

7966.1;5 LSPP-LS

Project title

Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease
Abstract (English)	The objective of this collaboration is the preclinical development of a humanized antibody, in particular a humanized single-chain (scFv) antibody fragment for the treatment and prevention of Alzheimer¿s Disease. For this reason the mechanism of action of various antibody fragments as well as pharmacokinetic and pharmacodynamic properties of an existing lead antibody (ESBA212), the latter resulting from a scientific collaboration between Prof. Nitsch and ESBATech, shall be characterized in detail in vivo in animal models of passive immunization of Alzheimer¿s Disease.

Category

Text

Short description
(English)

Preclinical development of a humanized scFv antibody for prevention and treatment of Alzheimer¿s disease

Abstract
(English)

The objective of this collaboration is the preclinical development of a humanized antibody, in particular a humanized single-chain (scFv) antibody fragment for the treatment and prevention of Alzheimer¿s Disease. For this reason the mechanism of action of various antibody fragments as well as pharmacokinetic and pharmacodynamic properties of an existing lead antibody (ESBA212), the latter resulting from a scientific collaboration between Prof. Nitsch and ESBATech, shall be characterized in detail in vivo in animal models of passive immunization of Alzheimer¿s Disease.